🔥Telegram İfşa

Today was the day we walked for Nora ❤️ Thank you to everyone who contributed to this effort to end childhood cancer, whether it be physically or financially. I’m so blessed to call this team mine! Now the hard work continues in the lab.

Excited to report our newest preprint is now available! Herein we find that expanding human CART cells with an AMPK agonist rewires their metabolism and significantly improves anti-leukemia survival in an xenograft model. Check it out! Peds Heme/Onc at UPMC Children's Hosp Pittsburgh Craig Byersdorfer

Cancer escapes immunotherapies by mutating its surface. This means even groundbreaking #CARTCell therapies fail too often because of cancer resistance. But what if we could use #GenerativeAI to design CAR-T with de novo binders faster and smarter, targeting even resistant tumors?

Teaching this crew to make virus in the ultracentrifuge today after they successfully cloned and generated their own CAR plasmids 🧬🦠 Super proud mentor 🥹

Amazing talk by Dr. Ayana Ruffin ⁦Dr.YayaTheScientist⁩ ⁦Winship Cancer Institute of Emory University⁩ on the importance of CD2 in adoptive immunotherapy of cancer. It’s a T:B thing. #2025SIS⁩ on the UVA campus.

Had the opportunity to chair the session for rockstar speakers Chrystal Paulos and Dr.YayaTheScientist at #2025SIS today. Love seeing my mentor-for-life and her trainees crush it! Th17 cells and CD2 for the win! 🧬

#ScienceSaturday ❓How can we help CAR T cells survive longer and fight tumors more effectively? ➡️ In this study, Bailey et al. found that deleting the interferon-γ receptor (IFN-γR) in CAR T cells prevents IFN-γ–induced cell death, especially in CD28-based CARs, leading to

I always love the schematics and overviews from ACIR. Thank you for providing this nice summary of our most recent work on IFNg-resistant CAR-T cells 🧫

Analyzing scRNAseq data from CAR T cell infusion products, Supper and Donner et al. found that VEGFR1 was expressed in 41BB.z CAR T cells and associated negatively with treatment response. bit.ly/3FW0PIi

Check out our new paper in Hepatology on how myeloid cells limit #immunotherapy in preclinical #cholangiocarcinoma models! Disease site matters! Collaborative effort with Chrystal Paulos and many others Winship Cancer Institute of Emory University Sidney Kimmel Comprehensive Cancer Center Vanderbilt University pubmed.ncbi.nlm.nih.gov/40590857/

Congrats Rishab Ramapriyan, MD and collaborators MGB Neurosurgery on our work developing Meso-CAR T cells for refractory meningiomas, published this week SNO! doi.org/10.1093/neuonc…

Online Now: Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity dlvr.it/TM5t9j

BREAKING: We uncovered a potent immune alliance that could change how we treat solid tumors. Published in Cancer Cell , we show that Th17 cells *must* work with B cells to eliminate tumors—and keep it from coming back. 📄 cell.com/cancer-cell/fu… 🧵1/12👇Let’s walk through it:

I am thrilled to finally share my lab's first paper showing that sucralose consumption reduces immunotherapy efficacy in cancer, published NOW in Cancer Discovery ! Let's break it down. 1/n aacrjournals.org/cancerdiscover…

🚨New in @JITCancer! Thrilled to share our position article, co-led w/Dr. Posey Avery Posey, on engineering next wave of antibody & cell therapies. Let’s build the future of immuno-oncology.🧵 #NextGenIO Penn Medicine Winship Cancer Institute of Emory University Society for Immunotherapy of Cancer 🔗 jitc.bmj.com/content/13/8/e…

You know those group projects where half the team quits, those who do show can’t agree, and the final product is something only a mother would love? This was the opposite. This team was AMAZING to work with and this is 100% worth reading. Check it out! jitc.bmj.com/content/13/8/e…

New #JITC position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs Stefanie Bailey Kyle G Daniels Christopher Heery MD Gregory Lesinski Megen Wittling Chrystal Paulos Paulos Lab

CIC member Justin Taylor and team released a preprint showing they can predict patient outcomes in Merkel Cell Carcinoma—a fast-growing, aggressive cancer. Their work provides important insights into survival factors. Read more: immunology.virginia.edu/hrodriguezmcc_…